Fibrinogen Fragment X Mediates Endothelial Barrier Disruption via Suppression of VE-Cadherin
- 12 October 2023
- journal article
- research article
- Published by Elsevier in Journal of Surgical Research
- Vol. 293, 639-646
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R35GM146859)
- Aniara Diagnostica
This publication has 44 references indexed in Scilit:
- Early and individualized goal-directed therapy for trauma-induced coagulopathyScandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2012
- Peptide Bβ15-42 Preserves Endothelial Barrier Function in ShockPLOS ONE, 2009
- The VE‐cadherin binding domain of fibrinogen induces endothelial barrier permeability and enhances transendothelial migration of malignant breast epithelial cellsInternational Journal of Cancer, 2009
- Bβ15-42 (FX06) reduces pulmonary, myocardial, liver, and small intestine damage in a pig model of hemorrhagic shock and reperfusion*Critical Care Medicine, 2009
- Incorporation of Fragment X into Fibrin Clots Renders Them More Susceptible to Lysis by PlasminBiochemistry, 2006
- Endothelial Cell VE-cadherin Functions as a Receptor for the β15–42 Sequence of FibrinJournal of Biological Chemistry, 1998
- Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.Journal of Clinical Investigation, 1993
- Antifibrinolytic activities of alpha-N-acetyl-L-lysine methyl ester, epsilon-aminocaproic acid, and tranexamic acid. Importance of kringle interactions and active site inhibition.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992
- Effect of Fibrinogen Fragments D and E on the Adhesive Properties of Human Granulocytes to Venous Endothelial CellsPathophysiology of Haemostasis and Thrombosis, 1991
- Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator.Journal of Clinical Investigation, 1987